(PharmaNewsWire.Com, March 16, 2017 ) The Global Pharmaceutical Excipients Market was worth $5.68 billion in 2016 and estimated to be growing at a CAGR of 6.1%, to reach $7.64 billion by 2021. An excipient is a natural or synthetic constituent formulated alongside the active ingredient of a medication, included for the purpose of inducing and catalysing a wide range of physical and chemical properties.
The Global market for Pharmaceutical Excipients market is broadly categorized by Product, by Functionality and by Formulation Type. Based on Product it is further categorized into Organic Chemicals (Oleochemicals, Carbohydrates, Petrochemicals, Proteins, Other Organic Chemicals) and Inorganic Chemicals (Calcium Phosphates, Metal Oxides, Halites, Calcium Carbonates, Calcium Sulphates, Other Inorganic Chemicals). Based on Functionality the Pharmaceutical Excipients are divided into subcategories like Fillers & Diluents, Binders, Suspension & Viscosity Agents, Coatings, Disintegrants, Flavouring Agents, Lubricants & Glidants, Colorants, Preservatives, Others). On basis of type of formulations, it is segmented into Oral Formulations, Topical Formulations, Parenteral Formulations and Advanced Delivery Systems. The fillers & diluents segment accounted for the largest share of the pharmaceutical excipients market while the lubricant & Glidants segment will witness the highest growth.
On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Europe and North America occupy the majority of the share in market, accounting for almost 2/3 of the revenue. Despite that Asia-Pacific remains the dominant region in terms of growth because of the untapped resources it offers in terms of manufacturing facilities and sheer population figures.
Rise in chronic diseases due to sedentary life style, heavy investments by the pharmaceutical companies in development of biologics, adopting modern innovations like nanotechnology are key driving forces of the market. Reducing side-effects of drugs and developing eco-friendly solutions for manufacturing processes are the major challenge faced by the pharmaceutical industry.
As discussed earlier, demand is increasing in the emerging markets like Asia-Pacific and Latin America, therefore proper expansion strategies, launching new product pipeline would be a lucrative opportunity for the companies operating in this industries. However, the growth of the market is hindered to a certain level by the fact that investments in R&D by major companies are not up to the required level and increasing regulatory requirements are making it increasingly hard to get new manufacturing facilities approved which are definite threats to overcome.
Emerging players in this market are giving a stiff competition to the top 10 players who occupy almost 70% of the total market. It can be attributed to the rapid growth of the market and opportunities it possesses in developing countries. Some of the key players operating in the field are Ashland Inc., AkzoNobel, Archer Daniels Midland Company, Associated British Foods PLC, BASF SE, Colorcon, Inc., Croda International PLC, Evonik Industries AG, FMC Corporation, Innophos Holdings Inc., J.M. Huber Corporation, Merck Millipore, Roquette Group, The DOW Chemical Company and Lubrizol Corporation.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
